| Code | CSB-RA023994MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Amlitelimab, targeting TNFSF4 (tumor necrosis factor superfamily member 4), also known as OX40 ligand (OX40L). TNFSF4 is a type II transmembrane protein primarily expressed on activated antigen-presenting cells, including dendritic cells, B cells, and macrophages. It functions as a critical costimulatory molecule in T cell activation and immune responses by binding to its receptor OX40 on activated T cells. Dysregulated TNFSF4/OX40L signaling has been implicated in various autoimmune and inflammatory conditions, including atopic dermatitis, inflammatory bowel disease, and other immune-mediated disorders.
Amlitelimab represents a therapeutic antibody designed to modulate immune responses by blocking the OX40-OX40L interaction, thereby dampening excessive T cell activation and inflammatory cascades. This biosimilar antibody provides researchers with a valuable tool for investigating TNFSF4-mediated immune mechanisms, studying costimulatory pathway biology, and exploring potential therapeutic interventions in autoimmune disease models. It enables mechanistic studies of T cell regulation and immune tolerance in various experimental contexts.
There are currently no reviews for this product.